# A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

> **NCT06453668** · PHASE1 · RECRUITING · sponsor: **ITB-Med LLC** · enrollment: 48 (estimated)

## Conditions studied

- ALS

## Interventions

- **BIOLOGICAL:** TCD601

## Key facts

- **NCT ID:** NCT06453668
- **Lead sponsor:** ITB-Med LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-16
- **Primary completion:** 2029-11
- **Final completion:** 2029-11
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06453668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06453668, "A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06453668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*